A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis.
J Eur Acad Dermatol Venereol
; 37(5): 1046-1055, 2023 May.
Article
em En
| MEDLINE
| ID: mdl-36606551
ABSTRACT
BACKGROUND:
Evaluation of effectiveness and safety of new systemic treatments for atopic dermatitis (AD) after approval is important. There are few published data exceeding 52-week therapy with dupilumab.OBJECTIVES:
To examine the safety, effectiveness and drug survival of dupilumab in a Danish nationwide cohort with moderate-to-severe AD up to 104 weeks exposure.METHODS:
We included 347 adult patients with AD who were treated with dupilumab and registered in the SCRATCH registry during 2017-2022.RESULTS:
At all visits, we observed improvement in AD severity measured by Eczema Area and Severity Index (EASI) [median (IQR)]. EASI score at baseline was 18.0 (10.6-25.2), at week 4 6.5 (3.5-11.6), at week 16 3.7 (1.2-6.2), at week 52 2.0 (0.8-3.6), at week 104 1.7 (0.8-3.8). While drug survival was high (week 52 90%; week 104 86%), AD in the head-and-neck area remained present in most patients at high levels; proportion with head-and-neck AD at baseline was 76% and 68% at week 104. 35% of patients reported any AE. Conjunctivitis was the most frequent (25% of all patients) and median time to first registration of conjunctivitis was 201 days.CONCLUSIONS:
While 2-year drug survival was 86%, dupilumab was unable to effectively treat AD in the head-and-neck area, and conjunctivitis was found in 25% of patients.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Conjuntivite
/
Dermatite Atópica
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Humans
Idioma:
En
Revista:
J Eur Acad Dermatol Venereol
Assunto da revista:
DERMATOLOGIA
/
DOENCAS SEXUALMENTE TRANSMISSIVEIS
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Dinamarca